Screening, Diagnosis and Management of Atrial Fibrillation in Cancer Patients: Current Evidence and Future Perspectives.
Pedro Gonçalves-TeixeiraTelma CostaIsabel FragosoDiogo FerreiraMariana BrandãoAdelino F Leite-MoreiraFrancisco SampaioJosé RibeiroRicardo Fontes-CarvalhoPublished in: Arquivos brasileiros de cardiologia (2022)
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population, carrying a high morbimortality burden, and this also holds true in cancer patients. The association between AF and cancer goes even further, with some studies suggesting that AF can be a marker of occult cancer. There is, however, a remarkable paucity of data concerning specific challenges of AF management in cancer patients. AF prompt recognition and management in this special population can lessen the arrhythmia-related morbidity and have an important prognostic benefit. This review will focus on current AF diagnosis and management challenges in cancer patients, with special emphasis on AF screening strategies and devices, and anticoagulation therapy with non-vitamin K antagonist oral anti-coagulants (NOACs) for thromboembolic prevention in these patients. Some insights concerning future perspectives for AF prevention, diagnosis, and treatment in this special population will also be addressed.
Keyphrases
- atrial fibrillation
- catheter ablation
- oral anticoagulants
- left atrial
- left atrial appendage
- direct oral anticoagulants
- papillary thyroid
- heart failure
- percutaneous coronary intervention
- squamous cell
- newly diagnosed
- ejection fraction
- stem cells
- end stage renal disease
- risk factors
- machine learning
- chronic kidney disease
- squamous cell carcinoma
- deep learning
- mesenchymal stem cells
- drug induced
- case control
- replacement therapy